It has been about a month since the last earnings report for Chemed (CHE). Shares have added about 9.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Chemed due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Chemed Misses Q2 Earnings Estimates
Chemed Corporation reported second-quarter 2025 adjusted earnings per share of $4.27, down 21.9% year over year. The figure fell short of the Zacks Consensus Estimate by 10.67%.
The company’s GAAP earnings per share were $3.57, down 23.2% from last year’s reported figure.
Chemed’s Q2 Revenues
Revenues in the reported quarter improved 3.8% year over year to $618.8 million. The metric topped the Zacks Consensus Estimate by 0.45%.
Chemed Updates 2025 Guidance
The company revised its full-year 2025 guidance. Revenues from VITAS, before Medicare Cap, are now estimated to increase 7.5% to 8.5% (earlier 10.5% to 11.3%) from the 2024 levels.
The Zacks Consensus Estimate for total revenues is pegged at $2.55 billion, which indicates a 4.9% improvement year over year.
Adjusted earnings are anticipated in the range of $22.00-$22.30 per share (previously $24.95-$25.45 range). The Zacks Consensus Estimate for the metric is pegged at $22.12, which implies a 4.4% fall over the 2024 adjusted figure.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month.
The consensus estimate has shifted -5.56% due to these changes.
VGM Scores
At this time, Chemed has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Chemed has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry Player
Chemed belongs to the Zacks Medical - Outpatient and Home Healthcare industry. Another stock from the same industry, Quest Diagnostics (DGX), has gained 6.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2025.
Quest Diagnostics reported revenues of $2.76 billion in the last reported quarter, representing a year-over-year change of +15.2%. EPS of $2.62 for the same period compares with $2.35 a year ago.
Quest Diagnostics is expected to post earnings of $2.51 per share for the current quarter, representing a year-over-year change of +9.1%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.1%.
Quest Diagnostics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Chemed Corporation (CHE): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
